Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Mastercard (MA) has pulled back to roughly $522 after a sharp slide from the $600s, leaving the stock oversold (RSI ~29.9) and well below its 20- and 50-day averages. With earnings due 01/29/2026 and consumer spending described as holding firm in recent coverage, MA sets up as a tactical long: defined risk below recent lows and upside toward the fi…
Wix.com Ltd. shares rose sharply after the company’s board approved a $2 billion share repurchase program spanning fiscal years 2026-2027. The authorization permits purchases of ordinary shares and convertible notes via open market and private transactions, to be funded by cash on hand, operating cash flow, or potentially new capital. The program i…
Ryanair's chief executive says the carrier could provide free Wi-Fi on every aircraft within three to five years as connectivity technology evolves to remove current fuel costs associated with rooftop antennas. The CEO also reiterated that governments, not airlines, should fund measures to prevent drone incursions that have disrupted European fligh…
Mobico Group reported that a subsidiary is in advanced negotiations with five public transport authorities in Germany to adjust rail service contracts across North Rhine-Westphalia and nearby regions. The announcement coincided with a more than 13% rise in the group's shares as markets reacted to the prospect of contract realignment intended to cre…
Goldman Sachs has reaffirmed a Neutral rating and a $223.00 price target on AbbVie as the company prepares to issue 2026 guidance alongside fourth-quarter 2025 results on February 4. The bank highlights investor debate over competitive pressures for Skyrizi and Rinvoq and notes management will stop updating mid-term guidance for those products. Gol…
JPMorgan raised its price target on Corning to $115 from $100 and kept an Overweight rating following the announcement of a multiyear supply agreement with Meta worth up to $6 billion. The pact is expected to support Meta’s data center expansion and spur additional investment in Corning’s North Carolina manufacturing footprint, including a new opti…
JPMorgan reaffirmed an Overweight rating on ASML and set a $1,518 price target, citing a substantial beat in fourth-quarter 2025 orders. The company reported record revenue and robust bookings that suggest stronger results ahead, while select valuation metrics indicate the stock may be rich relative to fair value.
Residents of Silwan in East Jerusalem report receiving eviction orders that favor Ateret Cohanim, a settler organization that has acquired dozens of properties in the district. Dozens of families have been told to leave under a Supreme Court order, with deadlines tied to the end of Ramadan - mid-March - while tensions over settlement activity and a…
Birkenstock has set a target of generating 1 billion euros in incremental revenue across the next three years, aiming for annual top-line growth of 13%-15% at constant currencies. The company expects double-digit expansion in the Americas and EMEA, a doubling of its Asia-Pacific business, and adjusted EPS to grow about 200 basis points faster than …
U.S. stock futures inched higher ahead of the Federal Reserve rate decision, with several corporate earnings reports and operational updates steering premarket activity. Telecom, chipmakers and data-storage names led gains, while a handful of industrial and consumer-facing firms fell despite some beating quarterly estimates.
Morgan Stanley expects most European aerospace and defence firms to meet or beat forecasts for fiscal 2025 and has revised its sector preferences. The bank highlights Rolls-Royce as the leading aerospace pick and Rheinmetall in defence, while signalling that management commentary around 2026 will carry greater weight than FY25 headlines.
Saudi Arabia's stock market ended the trading day higher, with the Tadawul All Share index climbing 0.67% to a one-month high. Gains were concentrated in the Insurance, Petrochemicals and Industrial Investment sectors, while market breadth was mixed as more stocks fell than rose. Commodity prices for crude, Brent and gold moved higher, and key curr…
Travis Kelce will take a stake of under 5% in Sleep Number and serve as a national advertising spokesman for the mattress maker over the next three years. The deal includes a combination of purchased shares and restricted stock that vests over three years. The move comes as Sleep Number pursues a turnaround under new CEO Linda Findley amid declinin…
Corning projected first-quarter core sales above analysts' estimates, driven by steady demand for its fiber-optic products, which account for nearly 40% of company revenue. The company highlighted ongoing investment in optical communications and announced a potential up to $6 billion multi-year supply agreement with Meta Platforms for AI-focused da…
H.C. Wainwright has reaffirmed a Buy rating and a $10.00 price target on Cardiff Oncology (CRDF) after the company disclosed updated clinical results from its CRDF-004 trial. The price target implies notable upside versus the current roughly $2 share price. Trial findings and upcoming regulatory and clinical milestones are informing near-term inves…
BMO Capital raised its price objective on Stride Inc. (NYSE: LRN) to $94 from $75 while retaining a Market Perform rating, citing fiscal second-quarter 2026 results that beat expectations largely due to a one-time gain. Management reaffirmed full-year revenue guidance and raised adjusted operating income expectations, even as core General Education…
H.C. Wainwright retained its Buy rating on Kazia Therapeutics and affirmed an $18.00 price target after the company released updated Phase 1b data for paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer (TNBC). The small-cap biotech, trading at $7.15 with a market capitalization of $77…
President Donald Trump issued a public ultimatum urging Iran to negotiate a nuclear deal or face a more severe U.S. military response, writing that time is running out and calling for an agreement with "NO NUCLEAR WEAPONS." He said the previous warning led to a strike and warned that the next attack would be "far worse," while also asserting that a…
UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…
In the first weeks of 2026, numerous U.S. companies across technology, consumer, manufacturing, logistics and financial sectors have announced workforce reductions. The moves are framed as cost-cutting, operational consolidation and resource reallocation toward artificial intelligence and cloud initiatives. The rounds of cuts range from several hun…
F5 Networks reported first-quarter fiscal 2026 results that outperformed expectations, prompting an upward revision to full-year guidance while leaving some analysts cautious. The company beat revenue and EPS forecasts, posted strong margins and notable regional and segment gains, yet Needham preserved a Hold rating pending more sustained outperfor…
H.C. Wainwright reaffirmed its Buy rating and $60 price target for Maze Therapeutics (MAZE), citing a potential regulatory shortcut enabled by pediatric extrapolation for APOL1-mediated kidney disease. Multiple analysts have adjusted models and initiated coverage over recent weeks, reflecting heightened optimism ahead of a pivotal Phase 2 HORIZON r…
Evercore ISI raised its price target on Viridian Therapeutics to $45 from $44 while keeping an Outperform rating as the company approaches Phase 3 subcutaneous thyroid eye disease (TED) data expected in Q1 2026. The new target implies roughly 34% upside from the stock's then-current price of $33.54. The research house highlighted the importance of …
H.C. Wainwright raised its price target on Hecla Mining to $36.50 from $16.50 and kept a Buy rating after the miner reported stronger production across silver, gold, lead and zinc. The firm pointed to robust silver market demand and operational improvements, while market metrics show the stock trading at elevated multiples.
H.C. Wainwright has kept a Buy rating and a $16.00 price target on Aclaris Therapeutics (ACRS) after the company reported encouraging preclinical outcomes for ATI-2138 in a severe alopecia areata mouse model. The study, conducted by Dr. Angela Christiano at Columbia University, showed rapid and near-complete hair regrowth that outperformed Pfizer’s…
